#1 Clinical Trials Search in Europe

Nizatidine

Nizatidine, a histamine H2-receptor antagonist, has been the subject of several clinical trials investigating its efficacy in various medical conditions. This article summarizes key findings from clinical studies examining nizatidine’s use in treating gastroesophageal reflux disease (GERD), preventing weight gain in schizophrenia patients, and its potential interactions with other medications.

Table of Contents

What is Nizatidine?

Nizatidine, also known by its brand name Axid, is a medication that belongs to a class of drugs called histamine-2 receptor antagonists (H2RAs)[1]. These medications work by reducing the amount of acid produced in the stomach. Nizatidine is commonly used to treat various gastric (stomach) conditions and is available in different forms, including capsules and oral solutions[2].

Uses of Nizatidine

Nizatidine is primarily used to treat the following conditions:

  • Gastroesophageal Reflux Disease (GERD): This is a condition where stomach acid frequently flows back into the esophagus (the tube connecting your mouth and stomach), causing heartburn and other symptoms[3].
  • Gastritis: This refers to inflammation of the stomach lining, which can cause pain, nausea, and other digestive issues[4].
  • Peptic Ulcers: These are sores that develop on the lining of the stomach or small intestine, often causing pain and discomfort[1].

In some cases, nizatidine is also used to prevent ulcers in patients who are taking non-steroidal anti-inflammatory drugs (NSAIDs) for long periods[5].

How Nizatidine Works

Nizatidine works by blocking the action of histamine on the cells in the stomach that produce acid. Histamine is a natural substance in the body that stimulates these cells to produce acid. By blocking histamine, nizatidine reduces the amount of acid produced in the stomach[1]. This helps to relieve symptoms of conditions like GERD and gastritis, and allows ulcers to heal.

Administration and Dosage

Nizatidine is typically taken orally in the form of capsules or oral solution. The dosage and frequency of administration can vary depending on the condition being treated and the individual patient’s needs. Some common dosages include:

  • For adults with active ulcers: 300 mg once daily at bedtime or 150 mg twice daily[1].
  • For GERD: 150 mg twice daily[1].

It’s important to follow your doctor’s instructions carefully when taking nizatidine. The medication can be taken with or without food[6].

Potential Side Effects

Like all medications, nizatidine can cause side effects, although not everyone experiences them. Common side effects may include:

  • Headache
  • Dizziness
  • Nausea
  • Diarrhea
  • Constipation

If you experience any severe or persistent side effects, it’s important to contact your healthcare provider[2].

Drug Interactions

Nizatidine can interact with other medications. One notable interaction is with metformin, a medication used to treat diabetes. Some studies have suggested that nizatidine may affect how the body processes metformin, potentially increasing its levels in the blood[5]. Always inform your doctor about all medications you’re taking, including over-the-counter drugs and supplements.

Ongoing Research

Researchers continue to study nizatidine for potential new uses. Some areas of investigation include:

  • Weight Management in Schizophrenia: Some studies are looking at whether nizatidine can help manage weight gain in patients with schizophrenia who are taking certain antipsychotic medications[7].
  • Combination Therapy: Researchers are studying the effectiveness of combining nizatidine with other medications, such as rebamipide, for treating gastritis[4].
  • Effects on Heme Oxygenase 1: Some research is exploring whether nizatidine can increase levels of a protein called heme oxygenase 1, which may have protective effects in the body[8].

These ongoing studies may lead to new uses for nizatidine in the future, but more research is needed before any definitive conclusions can be drawn.

Aspect Details
Primary Uses Treatment of GERD, gastritis, excess stomach acid
Dosages Studied 150 mg, 300 mg
Population Groups Adults, infants (30 days to 1 year)
Combination Therapies Studied with metformin, rebamipide, olanzapine
Key Study Types Bioequivalence, pharmacokinetic interactions, efficacy in GERD
Potential New Applications Weight gain management in schizophrenia, modulation of heme oxygenase 1

FAQ

  • What is nizatidine used for? Nizatidine is primarily used to treat gastroesophageal reflux disease (GERD), gastritis, and other conditions related to excess stomach acid. It has also been studied for potential uses in preventing weight gain in schizophrenia patients taking olanzapine.
  • How does nizatidine compare to other similar medications? Clinical trials have compared nizatidine to other medications like rebamipide for treating gastritis. Some studies have also examined its effectiveness when combined with other drugs, such as metformin for diabetes management.
  • Are there any potential drug interactions with nizatidine? Yes, some studies have investigated potential interactions between nizatidine and other medications. For example, one trial examined the pharmacokinetic interaction between metformin and nizatidine in healthy volunteers.
  • Has nizatidine been studied in pediatric populations? Yes, there has been at least one clinical trial investigating the use of nizatidine (Axid) in infants aged 30 days to 1 year for the treatment of gastroesophageal reflux disease (GERD) symptoms.
  • What are some common dosages of nizatidine used in clinical trials? Clinical trials have used various dosages of nizatidine, including 150 mg and 300 mg. For example, one study examined the bioequivalence of nizatidine 300 mg capsules under fasting and non-fasting conditions.

Ongoing Clinical Trials on Nizatidine

  • Study of SKB264 and Pembrolizumab for Treating Patients with Advanced Non-Small Cell Lung Cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Romania Spain

  • Study of SKB264 for Patients with Advanced Solid Tumors Not Responding to Standard Treatments

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy Spain

Glossary

  • Bioequivalence: A term used to describe when two medications have the same active ingredient and produce the same effect in the body. In clinical trials, bioequivalence studies compare how different formulations of a drug are absorbed and processed by the body.
  • Gastroesophageal Reflux Disease (GERD): A digestive disorder that occurs when stomach acid frequently flows back into the esophagus, causing symptoms such as heartburn and regurgitation.
  • Histamine H2-receptor antagonist: A type of medication that reduces stomach acid production by blocking histamine receptors in the stomach lining. Nizatidine belongs to this class of drugs.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body. This information helps determine appropriate dosing and potential drug interactions.
  • Prokinetic: A type of medication that enhances gastrointestinal motility, helping to move food and waste through the digestive system more quickly.
  • Gastroparesis: A condition where the stomach takes too long to empty its contents, leading to symptoms such as nausea, vomiting, and feeling full quickly.
  • Heme Oxygenase 1 (HO-1): An enzyme that plays a role in protecting cells against oxidative stress and has been studied in relation to gastroparesis and other digestive disorders.
  • Interstitial Cells of Cajal: Specialized cells in the digestive tract that help regulate the rhythmic contractions of the gut, playing a crucial role in gastrointestinal motility.

References

  1. https://clinicaltrials.gov/study/NCT01161940
  2. https://clinicaltrials.gov/study/NCT00373334
  3. https://clinicaltrials.gov/study/NCT02555852
  4. https://clinicaltrials.gov/study/NCT05072938
  5. https://clinicaltrials.gov/study/NCT01409395
  6. https://clinicaltrials.gov/study/NCT01161927
  7. https://clinicaltrials.gov/study/NCT00486005
  8. https://clinicaltrials.gov/study/NCT02232308